namdrc membership for pulmonary medicine | …comes, such as mortality and complications, patient...

September 2018 www.namdrc.org VOLUME 28 No. 9

The 2019 Medicare IPPS and OPPS On July 25, The Centers for Medicare and Medicaid Services (CMS) released the 2019 Outpatient Prospective Payment System (OPPS) proposed rule and on August 2 the Agency released the finalized In-patient Prospective Payment Rule (IPPS). CMS has stated that it is focusing on regulatory reform and reducing the regulatory burden for physicians and hospitals. The finalized 2019 IPPS rule makes adjust-ments to the four hospital pay-for-reporting and value-based pur-chasing quality programs. These changes will begin to reduce the documentation burden imposed on physicians practicing in the hos-pital environment. The changes also signal the direction CMS will be taking for the physician Quality Payment Program in the future. The final inpatient rule provides acute care hospitals an average payment increase of approximately 3 percent, which reflects rate updates re-quired by law. On the other hand, CMS continues to advance its Site Neutral Payment Policy under the OPPS which will affect physician practices that have been acquired by hospital organizations and the ability to expand pulmonary rehabilitation programs.

Outpatient Prospective Payment System Under the Site Neutral Payment Policy, CMS proposes to pay for services at a “non-excepted”, hospital owned, off-campus provider-based department using the Physicians Fee Schedule rather than the more generous Outpatient Prospective Payment System to con-trol for “unnecessary increases in utilization of outpatient services.” An excepted hospital out-patient department will still be paid under the OPPS if it meets the relocation and change of ownership require-ments adopted in the 2017 OPPS final rule. CMS it trying to put a stop to hospitals purchasing existing independent physician practic-es resulting in practices, previously paid under the PFS, furnishing services that are paid at OPPS rates, increasing the cost of care both to CMS and patients. Additionally, CMS is proposing to pay for services for new clinical families of services that are specifically fur-nished at off-campus provider-based departments under the PFS, instead of the OPPS. This will result in a significant drop in income for many of these facilities. CMS estimates Medicare savings to be $760 million for 2019. Furthermore, CMS proposes to expand the agency’s payment reductions for drugs purchased under the 340B

WASHINGTON WATCHLINE

PHYSICIAN ADVOCACY FOR EXCELLENCE IN THE DELIVERY OF PULMONARY, CRITICAL CARE AND SLEEP MEDICINE

The WASHINGTON WATCHLINE is pub-lished monthly and provides timely information to NAMDRC members on pending legislative and regulatory issues that impact directly on the practice of pulmonary medicine. NAMDRC’s primary mission is to improve access to quality care for patients with respiratory disease by removing regulatory and legislative barriers to appropriate treatment.

INSIDE THIS ISSUE About NAMDRC………..….……….7 Membership Benefits…...…………..7 NAMDRC New Membership Opportunities......................................8 NAMDRC Leadership……................3 Product and Technology News-

Genentec/Esbriet Article…...…...4

NAMDRC 42nd Annual Meeting and Educational Conference will be held:

March 14 – 16, 2019 Fairmont Sonoma Mission Inn

Sonoma, CA

NAMDRC 8618 Westwood Center Drive, Suite 210 Vienna, VA 22182-2273 Phone: 703-752-4359 Fax: 703-752-4360 Email: [email protected] “NAMDRC will directly affect your practice more than any other organiza-tion to which you belong.”

mailto:[email protected]

NAMDRC—WASHINGTON WATCHLINE

September 2018 VOLUME 28 NO 9

Drug Pricing Program and administered in the outpatient setting. CMS proposes to pay the average sales price (ASP) minus 22.5 percent for 340B-acquired drugs that are furnished by non-excepted off-campus provider-based departments.

IPPS Meaningful Measures Under new leadership, CMS has determined that having the same quality measure in multiple quali-ty payment programs adds unnecessary complexity and cost to those programs. In the final 2019 IPPS, CMS is removing unnecessary, redundant and process-driven measures from several pay-for-reporting and pay-for-performance quality programs. This includes certain measures that are in multiple programs, keeping them in the program where CMS believes they will be most effective. In all, these changes will remove a total of 18 measures from all programs and reduce 25 duplicative measures to a single program. The majority of these measures will be removed from the Hospital Inpatient Quality Reporting program (IQR). Measures to be removed from the IQR include all of the 30 day readmission measures since they are covered by the readmission reduction program. The measures that will remain, of interest to pulmonary physicians, for the 2019 data collection period include: Excess Days in Acute Care after Hospitalization for Pneumonia Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia Severe Sepsis and Septic Shock: Management Bundle Venous Thromboembolism Prophylaxis Intensive Care Unit Thromboembolism Prophylaxis Hospital Consumer Assessment of Healthcare Providers and Systems Survey CMS believes the Hospital Value Based Payment Program (VBP) should focus on measurement pri-orities not covered by the Hospital Readmissions Reduction Program or the Hospital Acquired Con-dition Reduction Program. The Hospital VBP Program will focus on measures related to clinical out-comes, such as mortality and complications, patient and caregiver experience, as measured using the HCAHPS survey, and healthcare costs, as measured using the Medicare Spending per Benefi-ciary measure. CMS will remove the three condition-specific payment measures including the pay-ment associated with a 30 day episode of care for pneumonia. However, for the 2019 data collection year CMS plans to add the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization to the VBP. The Hospital Readmissions Reduction Program includes six conditions: acute myocardial infarction, heart failure, pneumonia, chronic obstructive pulmonary disease, coronary artery bypass graft and total hip arthroplasty/total knee arthroplasty. After review of this program, CMS has determined that these six readmission measures, which are being removed from the IQR program, will remain unchanged in the readmission reduction program and no additional measures are currently being contemplated for this program.

Hospital Admission Orders In an interesting turn of events, after several meetings with stakeholders, CMS has decided to re-move the requirement that a physician order must be present in the medical record and be support-ed by the physician admission notes at the time of admission in order for the hospital to be paid

NAMDRC LEADERSHIP 2018-2019

OFFICERS Charles W. Atwood, MD President James P. Lamberti, MD President-Elect Maida V. Soghikian, MD Secretary/Treasurer Timothy A. Morris, MD Past President

Board of Directors Robert J. Albin, MD Albee Budnitz, MD Kent L. Christopher, MD Gerard J. Criner, MD Thomas B. Hazlehurst, MD Nicholas S. Hill, MD Theodore S. Ingrassia, III, MD Steve G. Peters, MD Kathleen F. Sarmiento, MD Chandan Saw, DO PRESIDENT’S COUNCIL George G. Burton, MD John Lore, MD Louis W. Burgher, MD, Ph.D. Alan L. Plummer, MD E. Neil Schachter, MD Frederick A. Oldenburg, Jr., MD Paul A. Selecky, MD Neil R. MacIntyre, MD Steven M. Zimmet, MD Peter C. Gay, MD Steve G. Peters, MD Lynn T. Tanoue, MD Dennis E. Doherty, MD

Executive Director Phillip Porte

Associate Executive Director/ Legislative Affairs Sarah Walter

Associate Executive Director Karen Lui, RN, MS

Director Member Services Vickie A. Parshall



for hospital inpatient services under Medicare Part A. However, physicians are still required to document relevant orders in the medical record to substantiate the medical necessity of the admission.

New Technology Applications Each year in the proposed IPPS rule, CMS addresses the applica-tions for new technology add-on payments by presenting its evalua-tion and analysis of the applications. CMS does not make pro-posals in the rule, but rather describes any concerns it may have with regard to whether a particular technology meets the criteria for payment as a new technology and seeks additional information for use in making a decision on the applications in the final rule. Includ-ed among the 15 applications for new technology add-on payment for 2019 is an application by Respicardia, Inc. for their transvenous phrenic nerve stimulator, the remedē® System and one from Porto-la Pharmaceuticals, Inc. for the use of AndexXa™. According to the Respicardia application, the remedē® System is indicated for use in the treatment of adult patients who have been diagnosed with moderate to severe central sleep apnea (CSA). The application has also suggested that this device is particularly suited for the treatment of CSA in patients who have been diagnosed with the comorbidity of heart failure. After consideration of the public comments CMS received, they have determined that the remedē® System meets all of the criteria for approval for new technology add-on payments. The maximum new technology add-on payment for a case involving the use of the remedē® System will be $17,250 for 2019. Portola Pharmaceuticals, Inc. submitted an application for new technology add-on payments for 2019 for the use of AndexXa™, an antidote used to treat patients who are receiving treatment with an oral Factor Xa inhibitor who suffer a major bleeding episode and require urgent reversal of direct and indirect Factor Xa anticoagula-tion. Currently there is no FDA-approved therapy for the urgent re-versal of any Factor Xa inhibitor in the event of a serious bleeding episodes. After consideration of the public comments, CMS has determined that AndexXa™ meets all of the criteria for approval for new technology add-on payments. The Agency has approved a new technology add-on payment for AndexXa™ of $14,062.50 for 2019.

The Ventilator-Associated Event (VAE) Outcome Measure. Since the inception of the Hospital Acquired Conditions program in 2007, CMS has tried to find a way to include ventilator associated pneumonia (VAP) or ventilator associated events (VAE) in the list of never events. The issue has been raised on an annual basis in the proposed IPPS and each year CMS receives comments oppos-ing the addition of VAE measures usually noting a lack of data on

PRODUCT AND TECHNOLOGY NEWS! NAMDRC is providing this space to our benefactors and patrons who provide us with

information about new products and innovations related to pulmonary medicine.

NAMDRC reserves the right to edit this copy as appropriate.

Genentech, a NAMDRC Industry Advisory Committee member, has submitted an Esbriet article entitled “ We won’t back down from IPF. Help preserve more lung function. Reduce lung function decline.” This article continues on the next two pages.



action on this issue for acute care hospitals but moved forward with ventilator quality measures for Long Term Care Hospitals (LTCH). CMS added the Ventilator-Associated Event Outcome Measure to the LTCH Quality Payment Program in 2015 “to monitor ventilator use and identify improvements in preventing complications associated with mechanical ventilation.” In the 2019 IPPS, CMS has decided to discard this measure for the 2020 payment year. LTCHs are no longer required to submit data on this measure beginning with October 1, 2018 admissions and discharges. In it’s place, CMS is adopting three other assessment-based quality measures on the topic of ventilator support: (1) Functional Outcome Measure: Change in Mobility among Long-Term Care Hospital Pa-tients ; (2) Compliance with Spontaneous Breathing Trials by Day 2 of the LTCH Stay; and (3) Ven-tilator Liberation Rate. CMS has collected data indicating that adherence to these three ventilator-related, assessment-based measures have reduced poor outcomes associated with the complica-tions of ventilator care, CMS may be inclined to migrate one or more of these measures to the acute hospital quality metrics in the future.

© 2018 Genentech USA, Inc. All rights reserved. ESB/021215/0039(5) 08/18

IndicationEsbriet® (pirfenidone) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Select Important Safety InformationElevated liver enzymes: Patients treated with Esbriet had a higher incidence of ALT and/or AST elevations of ≥3× ULN (3.7%) compared with placebo patients (0.8%). In some cases, these have been associated with concomitant elevations in bilirubin. No Esbriet-related cases of liver transplant or death due to liver failure have been reported. However, combined elevations of transaminases and bilirubin without evidence of obstruction is considered an important predictor of severe liver injury that could lead to death or the need for a transplant. Measure ALT, AST, and bilirubin levels prior to initiating Esbriet, then monthly for the first 6 months, and every 3 months thereafter. Dosage modifications or interruption may be necessary.Photosensitivity reaction or rash: Patients treated with Esbriet had a higher incidence of photosensitivity reactions (9%) compared with placebo patients (1%). Patients should avoid or minimize exposure to sunlight and sunlamps, regularly use sunscreen (SPF 50 or higher), wear clothing that protects against sun exposure, and avoid concomitant medications that cause photosensitivity. Dosage reduction or discontinuation may be necessary.Gastrointestinal (GI) disorders: Patients treated with Esbriet had a higher incidence of nausea, diarrhea, dyspepsia, vomiting, gastroesophageal reflux disease (GERD), and abdominal pain. GI events required dose reduction or interruption in 18.5% of 2403 mg/day Esbriet-treated patients, compared with 5.8% of placebo patients; 2.2% of 2403 mg/day Esbriet-treated patients discontinued treatment due to a GI event, compared with 1.0% of

placebo patients. The most common (>2%) GI events leading to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. Dosage modifications may be necessary.Adverse reactions: The most common adverse reactions (≥10%) were nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, GERD, sinusitis, insomnia, weight decreased, and arthralgia.Drug Interactions: CYP1A2 inhibitors: Concomitant use of Esbriet and strong CYP1A2 inhibitors (e.g., fluvoxamine) is not recommended, as CYP1A2 inhibitors increase systemic exposure of Esbriet. If discontinuation of the CYP1A2 inhibitor prior to starting Esbriet is not possible, dosage reductions of Esbriet are recommended. Monitor for adverse reactions and consider discontinuation of Esbriet.Concomitant use of ciprofloxacin (a moderate CYP1A2 inhibitor) at the dosage of 750 mg BID and Esbriet are not recommended. If this dose of ciprofloxacin cannot be avoided, dosage reductions of Esbriet are recommended, and patients should be monitored.Moderate or strong inhibitors of both CYP1A2 and other CYP isoenzymes involved in the metabolism of Esbriet should be avoided during treatment.CYP1A2 inducers: Concomitant use of Esbriet and strong CYP1A2 inducers should be avoided, as CYP1A2 inducers may decrease the exposure and efficacy of Esbriet. Specific Populations: Mild to moderate hepatic impairment: Esbriet should be used with caution in patients with Child Pugh Class A and B. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. Severe hepatic impairment: Esbriet is not recommended for patients with Child Pugh Class C. Esbriet has not been studied in this patient population.

Mild (CLcr 50-80 mL/min), moderate (CLcr 30-50 mL/min), or severe (CLcr <30 mL/min) renal impairment: Esbriet should be used with caution. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. End-stage renal disease requiring dialysis: Esbriet is not recommended. Esbriet has not been studied in this patient population. Smokers: Smoking causes decreased exposure to Esbriet which may affect efficacy. Instruct patients to stop smoking prior to treatment and to avoid smoking when using Esbriet.You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or to Genentech at 1-888-835-2555.Please see Brief Summary of Prescribing Information on adjacent pages for additional Important Safety Information.

References: 1. Esbriet Prescribing Information. Genentech, Inc. October 2017. 2. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; for the ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2014;371(12):1172]. N Engl J Med. 2014;370(22):2083–2092. 3. Noble PW, Albera C, Bradford WZ, et al; for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. 4. Data on file. Genentech, Inc. 2016.

Learn more about Esbriet and how to access medication at EsbrietHCP.com

IPF=idiopathic pulmonary fibrosis.* The safety and efficacy of Esbriet were evaluated in three phase 3,

randomized, double-blind, placebo-controlled, multicenter trials in which 1247 patients were randomized to receive Esbriet (n=623) or placebo (n=624).1 In ASCEND, 555 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo for 52 weeks. Eligible patients had percent predicted forced vital capacity (%FVC) between 50%–90% and percent predicted diffusing capacity of lung for carbon monoxide (%DLco) between 30%–90%. The primary endpoint was change in %FVC from baseline at 52 weeks.2 In CAPACITY 004, 348 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo. Eligible patients had %FVC ≥50% and %DLco ≥35%. In CAPACITY 006, 344 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo. Eligible patients had %FVC ≥50% and %DLco ≥35%. For both CAPACITY trials, the primary endpoint was change in %FVC from baseline at 72 weeks.3 Esbriet had a significant impact on lung function decline and delayed progression of IPF vs placebo in ASCEND.1,2 Esbriet demonstrated a significant effect on lung function for up to 72 weeks in CAPACITY 004, as measured by %FVC and mean change in FVC (mL).1,3,4 No statistically significant difference vs placebo in change in %FVC or decline in FVC volume from baseline to 72 weeks was observed in CAPACITY 006.1,3

† In clinical trials, serious adverse reactions, including elevated liver enzymes, photosensitivity reactions, and gastrointestinal disorders, have been reported with Esbriet. Some adverse reactions with Esbriet occurred early and/or decreased over time (ie, photosensitivity reactions and gastrointestinal events).1

‡ Esbriet Access Solutions offers a range of access and reimbursement support for your patients and practice. Clinical Coordinators are available to educate patients with IPF. The Esbriet® Inspiration Program™ motivates patients to stay on treatment.

§ The safety of pirfenidone has been evaluated in more than 1400 subjects, with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.1

WE WON’T BACK DOWN FROM IPF

STUDIED IN A RANGE OF PATIENTS

Clinical trials included patients

with IPF with a range of clinical characteristics,

select comorbidities, and concomitant

medications4

In clinical trials, Esbriet preserved

more lung function by delaying disease

progression for patients with IPF 1–4*

DEMONSTRATED EFFICACY

The safety and tolerability of Esbriet were

evaluated based on 1247 patients in 3 randomized, controlled trials1†

ESTABLISHED SAFETY AND

TOLERABILITY

More than 37,000 patients

have taken pirfenidone worldwide4§

WORLDWIDE PATIENT

EXPERIENCE

Genentech offers a breadth of patient

support and assistance services

to help your patients with IPF‡

COMMITTED TO PATIENTS

Help preserve more lung function. Reduce lung function decline.1–3

Rx only

BRIEF SUMMARYThe following is a brief summary of the full Prescribing Information for ESBRIET® (pirfenidone). Please review the full Prescribing Information prior to prescribing ESBRIET.

1 INDICATIONS AND USAGEESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

4 CONTRAINDICATIONSNone.

5 WARNINGS AND PRECAUTIONS5.1 Elevated Liver EnzymesIncreases in ALT and AST >3 × ULN have been reported in patients treated with ESBRIET. In some cases these have been associated with concomitant elevations in bilirubin. Patients treated with ESBRIET 2403 mg/day in the three Phase 3 trials had a higher incidence of elevations in ALT or AST ≥3 × ULN than placebo patients (3.7% vs. 0.8%, respectively). Elevations ≥10 × ULN in ALT or AST occurred in 0.3% of patients in the ESBRIET 2403 mg/day group and in 0.2% of patients in the placebo group. Increases in ALT and AST ≥3 × ULN were reversible with dose modification or treatment discontinuation. No cases of liver transplant or death due to liver failure that were related to ESBRIET have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury, that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to the initiation of therapy with ESBRIET in all patients, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary for liver enzyme elevations [see Dosage and Administration sections 2.1 and 2.3 in full Prescribing Information].

5.2 Photosensitivity Reaction or RashPatients treated with ESBRIET 2403 mg/day in the three Phase 3 studies had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). The majority of the photosensitivity reactions occurred during the initial 6 months. Instruct patients to avoid or minimize exposure to sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing that protects against sun exposure. Additionally, instruct patients to avoid concomitant medications known to cause photosensitivity. Dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash [see Dosage and Administration section 2.3 in full Prescribing Information].

5.3 Gastrointestinal DisordersIn the clinical studies, gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain were more frequently reported by patients in the ESBRIET treatment groups than in those taking placebo. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the ESBRIET 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common (>2%) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. The incidence of gastrointestinal events was highest early in the course of treatment (with highest incidence occurring during the initial 3 months) and decreased over time. Dosage modifications may be necessary in some cases of gastrointestinal adverse reactions [see Dosage and Administration section 2.3 in full Prescribing Information].

6 ADVERSE REACTIONSThe following adverse reactions are discussed in greater detail in other sections of the labeling:• Liver Enzyme Elevations [see Warnings and Precautions (5.1)]• Photosensitivity Reaction or Rash [see Warnings and Precautions (5.2)]• Gastrointestinal Disorders [see Warnings and Precautions (5.3)]

6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of pirfenidone has been evaluated in more than 1400 subjects with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.ESBRIET was studied in 3 randomized, double-blind, placebo-controlled trials

(Studies 1, 2, and 3) in which a total of 623 patients received 2403 mg/day of ESBRIET and 624 patients received placebo. Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to ESBRIET was 62 weeks (range: 2 to 118 weeks) in these 3 trials. At the recommended dosage of 2403 mg/day, 14.6% of patients on ESBRIET compared to 9.6% on placebo permanently discontinued treatment because of an adverse event. The most common (>1%) adverse reactions leading to discontinuation were rash and nausea. The most common (>3%) adverse reactions leading to dosage reduction or interruption were rash, nausea, diarrhea, and photosensitivity reaction. The most common adverse reactions with an incidence of ≥10% and more frequent in the ESBRIET than placebo treatment group are listed in Table 2.

Table 2. Adverse Reactions Occurring in ≥10% of ESBRIET-Treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3

Adverse Reaction

% of Patients (0 to 118 Weeks)

ESBRIET 2403 mg/day

(N = 623)

Placebo(N = 624)

Nausea 36% 16%

Rash 30% 10%

Abdominal Pain1 24% 15%

Upper Respiratory Tract Infection 27% 25%

Diarrhea 26% 20%

Fatigue 26% 19%

Headache 22% 19%

Dyspepsia 19% 7%

Dizziness 18% 11%

Vomiting 13% 6%

Anorexia 13% 5%

Gastro-esophageal Reflux Disease 11% 7%

Sinusitis 11% 10%

Insomnia 10% 7%

Weight Decreased 10% 5%

Arthralgia 10% 7%1 Includes abdominal pain, upper abdominal pain, abdominal distension, and stomach discomfort.

Adverse reactions occurring in ≥5 to <10% of ESBRIET-treated patients and more commonly than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), pruritus (8% vs. 5%), asthenia (6% vs. 4%), dysgeusia (6% vs. 2%), and non-cardiac chest pain (5% vs. 4%).6.2 Postmarketing ExperienceIn addition to adverse reactions identified from clinical trials the following adverse reactions have been identified during post-approval use of pirfenidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Blood and Lymphatic System DisordersAgranulocytosisImmune System DisordersAngioedemaHepatobiliary DisordersBilirubin increased in combination with increases of ALT and AST

7 DRUG INTERACTIONS7.1 CYP1A2 InhibitorsPirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6 and 2E1.Strong CYP1A2 InhibitorsThe concomitant administration of ESBRIET and fluvoxamine or other strongCYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to ESBRIET [see Clinical Pharmacology section 12.3 in full Prescribing Information]. Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during

ESBRIET® (pirfenidone)

ESB-100115_0470(2)_Brief Summary_MJAD.indd 1 3/27/17 10:07 AM

ESBRIET treatment. In the event that fluvoxamine or other strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended. Monitor for adverse reactions and consider discontinuation of ESBRIET as needed [see Dosage and Administration section 2.4 in full Prescribing Information].

Moderate CYP1A2 InhibitorsConcomitant administration of ESBRIET and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to ESBRIET [see Clinical Pharmacology section 12.3 in full Prescribing Information]. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see Dosage and Administration section 2.4 in full Prescribing Information]. Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily.Concomitant CYP1A2 and other CYP InhibitorsAgents or combinations of agents that are moderate or strong inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of ESBRIET (i.e., CYP2C9, 2C19, 2D6, and 2E1) should be discontinued prior to and avoided during ESBRIET treatment.

7.2 CYP1A2 InducersThe concomitant use of ESBRIET and a CYP1A2 inducer may decrease the exposure of ESBRIET and this may lead to loss of efficacy. Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology section 12.3 in full Prescribing Information].

8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy Risk Summary The data with ESBRIET use in pregnant women are insufficient to inform on drug associated risks for major birth defects and miscarriage. In animal reproduction studies, pirfenidone was not teratogenic in rats and rabbits at oral doses up to 3 and 2 times, respectively, the maximum recommended daily dose (MRDD) in adults [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.DataAnimal DataAnimal reproductive studies were conducted in rats and rabbits. In a combined fertility and embryofetal development study, female rats received pirfenidone at oral doses of 0, 50, 150, 450, and 1000 mg/kg/day from 2 weeks prior to mating, during the mating phase, and throughout the periods of early embryonic development from gestation days (GD) 0 to 5 and organogenesis from GD 6 to 17. In an embryofetal development study, pregnant rabbits received pirfenidone at oral doses of 0, 30, 100, and 300 mg/kg/day throughout the period of organogenesis from GD 6 to 18. In these studies, pirfenidone at doses up to 3 and 2 times, respectively, the maximum recommended daily dose (MRDD) in adults (on mg/m2 basis at maternal oral doses up to 1000 mg/kg/day in rats and 300 mg/kg/day in rabbits, respectively) revealed no evidence of impaired fertility or harm to the fetus due to pirfenidone. In the presence of maternal toxicity, acyclic/irregular cycles (e.g., prolonged estrous cycle) were seen in rats at doses approximately equal to and higher than the MRDD in adults (on a mg/m2

basis at maternal doses of 450 mg/kg/day and higher). In a pre- and post-natal development study, female rats received pirfenidone at oral doses of 0, 100, 300, and 1000 mg/kg/day from GD 7 to lactation day 20. Prolongation of the gestation period, decreased numbers of live newborn, and reduced pup viability and body weights were seen in rats at an oral dosage approximately 3 times the MRDD in adults (on a mg/m2 basis at a maternal oral dose of 1000 mg/kg/day).

8.2 Lactation Risk Summary

No information is available on the presence of pirfenidone in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. The lack of clinical data during lactation precludes clear determination of the risk of ESBRIET to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ESBRIET and the potential adverse effects on the breastfed child from ESBRIET or from the underlying maternal condition. Data

Animal DataA study with radio-labeled pirfenidone in rats has shown that pirfenidone or its metabolites are excreted in milk. There are no data on the presence of pirfenidone or its metabolites in human milk, the effects of pirfenidone on the breastfed child, or its effects on milk production.

8.4 Pediatric UseSafety and effectiveness of ESBRIET in pediatric patients have not been established.

8.5 Geriatric UseOf the total number of subjects in the clinical studies receiving ESBRIET, 714 (67%) were 65 years old and over, while 231 (22%) were 75 years old and over. No overall differences in safety or effectiveness were observed between older and younger patients. No dosage adjustment is required based upon age.

8.6 Hepatic ImpairmentESBRIET should be used with caution in patients with mild (Child Pugh Class A) to moderate (Child Pugh Class B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see Dosage and Administration section 2.3 in full Prescribing Information].The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with severe hepatic impairment. ESBRIET is not recommended for use in patients with severe (Child Pugh Class C) hepatic impairment [see Clinical Pharmacology section 12.3 in full Prescribing Information].

8.7 Renal ImpairmentESBRIET should be used with caution in patients with mild (CLcr 50–80 mL/min), moderate (CLcr 30–50 mL/min), or severe (CLcr less than 30 mL/min) renal impairment [see Clinical Pharmacology section 12.3 in full Prescribing Information]. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see Dosage and Administration section 2.3 in full Prescribing Information]. The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with end-stage renal disease requiring dialysis. Use of ESBRIET in patients with end-stage renal diseases requiring dialysis is not recommended.

8.8 SmokersSmoking causes decreased exposure to ESBRIET [see Clinical Pharmacology section 12.3 in full Prescribing Information], which may alter the efficacy profile of ESBRIET. Instruct patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET.

10 OVERDOSAGEThere is limited clinical experience with overdosage. Multiple dosages of ESBRIET up to a maximum tolerated dose of 4005 mg per day were administered as five 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation.In the event of a suspected overdosage, appropriate supportive medical care should be provided, including monitoring of vital signs and observation of the clinical status of the patient.

17 PATIENT COUNSELING INFORMATIONAdvise the patient to read the FDA-approved patient labeling (Patient Information).Liver Enzyme ElevationsAdvise patients that they may be required to undergo liver function testing periodically. Instruct patients to immediately report any symptoms of a liver problem (e.g., skin or the white of eyes turn yellow, urine turns dark or brown [tea colored], pain on the right side of stomach, bleed or bruise more easily than normal, lethargy) [see Warnings and Precautions (5.1)].Photosensitivity Reaction or RashAdvise patients to avoid or minimize exposure to sunlight (including sunlamps) during use of ESBRIET because of concern for photosensitivity reactions or rash. Instruct patients to use a sunblock and to wear clothing that protects against sun exposure. Instruct patients to report symptoms of photosensitivity reaction or rash to their physician. Temporary dosage reductions or discontinuations may be required [see Warnings and Precautions (5.2)].Gastrointestinal EventsInstruct patients to report symptoms of persistent gastrointestinal effects including nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain. Temporary dosage reductions or discontinuations may be required [see Warnings and Precautions (5.3)].SmokersEncourage patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET [see Clinical Pharmacology section 12.3 in full Prescribing Information].Take with FoodInstruct patients to take ESBRIET with food to help decrease nausea and dizziness.

Distributed by: Genentech USA, Inc. A Member of the Roche Group1 DNA Way, South San Francisco, CA 94080-4990

ESBRIET® (pirfenidone) ESBRIET® (pirfenidone)

ESBRIET® is a registered U.S. trademark of Genentech, Inc.© 2017 Genentech, Inc. All rights reserved. ESB/100115/0470(2) 2/17

ESB-100115_0470(2)_Brief Summary_MJAD.indd 2 3/27/17 10:07 AM



NAMDRC Membership Benefits AT A GLANCE...

Monthly publication of the Washington Watchline, providing timely information for practicing physicians;

Publication of Current Controversies focusing on one specific Pulmonary/Critical Care Issue in each publication;

Regulatory updates;

Discounted Annual Meeting registration fees;

The Executive Office Staff as a resource on a wide range of clinical and management issues; and

The knowledge that NAMDRC is an advocate for you and your profession.

https://www.namdrc.org/content/issue-advocacy

One of NAMDRC’s primary reasons for existence is to provide both clinicians and patients with the most up-to-date information regarding pulmonary medicine. Bookmark this page! The complexity of our nation’s health care system in general, and Medicare in particular, create a true chal-lenge for physicians and their office staffs. One of NAMDRC’s key strengths is to offer assistance on a myri-ad of coding, coverage and payment issues. In fact, NAMDRC members indicate that their #1 reason for belonging to and continuing membership in the Association is its voice before regulatory agencies and legislators. That effective voice is translated into providing members with timely information, identifying important Federal Register announcements, perti-nent statements and notices by the Centers for Medicare and Medicaid Services, the Durable Medical Equipment Regional Carriers, and local medical review policies.

ABOUT NAMDRC:

Established over three decades ago, the National Association for Medical Direction of Respiratory Care

(NAMDRC) is a national organization of physicians whose mission is to educate its members and address

regulatory, legislative and payment issues that relate to the delivery of healthcare to patients with respirato-

ry disorders.

NAMDRC members, all physicians, work in close to 2,000 hospitals nationwide, primarily in respiratory

care departments and critical/intensive care units. They also have responsibilities for sleep labs,

management of blood gas laboratories, pulmonary rehabilitation services, and other respiratory related

services.

https://www.namdrc.org/content/issue-advocacy



NEW MEMBERSHIP OPPORTUNITIES WITH NAMDRC

INSTITUTIONAL MEMBERSHIPS

NAMDRC is restructuring its membership opportunities to more accurately reflect how physicians practice medicine, ac-

knowledging that genuine “private practice” is nowhere near as prevalent today as it was even five years ago. Physicians

are now employees of hospitals and medical systems.

To improve our communication with you and hospital based colleagues, we are revamping our dues structure, with individ-

ual/small practice remaining basically the same as it is today. We are renaming our group practice options into two specif-

ic categories:

Institutional Membership/Gold for institutions that identify at least seven physicians, but no more than 20 physi-

cians as members of NAMDRC. Every identified physician will receive our monthly newsletter, the Washington

Watchline, and the institution will receive two half price registrations for our Annual Conference at the standard

member rate.

Institutional Membership/Platinum for institutions that identify at least 21, but no more than 50 physicians as mem-

bers of NAMDRC. Every identified physician will receive our monthly newsletter, the Washington Watchline, and

the institution will receive four half price registrations for our Annual Conference at the standard member rate.

Small Group Practice (1-6 physicians) $295 for renewal

$395 for new member (includes one-time $75 initiation fee.

Gold Institutional Membership $1750 (7-20 physicians) Platinum Institutional Membership $2500 (21 – 50 physicians) If you are based at a particular institution, we believe this is an excellent way to bring NAMDRC and its benefits to the at-tention of many of your colleagues. And the aggregate cost, per membership, drops dramatically under these new mem-bership categories.

RENEW NOW!

JOIN NOW!

Go to www.namdrc.org and join and/or renew your membership online.

http://www.namdrc.org

NAMDRC INSTITUTIONAL MEMBERSHIP APPLICATION Please select the category you are applying for:

□ Small Group Practice (1-6 physicians) $295/year for renewal

□ NEW Small Group Practice (1-6 Physicians) $395 for new member/year (includes one-time $75 initiation fee)

□ Gold Institutional Membership (7-20 physicians) $1750/year Includes two half price registrations for NAMDRC Annual Conference at the standard member rate.

□ Platinum Institutional Membership (21-50 physicians) $2500/year Includes two half price registrations for NAMDRC Annual Conference at the standard member rate. INSTITUTIONAL MEMBERSHIP INFORMATION Institutional Name: ______________________________________________________________________________________________ Contact Person:_________________________________________________________________________________________________ Email address: _________________________________________________________________________________________________ Address: _____________________________________________________________________________________________________ _______________________________________________________________________________________________________________ City: __________________________________________ State: __________________________ Zip: ___________________________ Phone: _______________________________________________ Fax: __________________________________________________ PAYMENT INFORMATION (Make check payable to “NAMDRC”) American Express MasterCard Visa

Credit Card Number__________________________________________ Expiration Date __________________CCV_________________

Name as it Appears on Credit Card __________________________________________________________________________________

Billing Address (If Different From Above) _____________________________________________________________________________

Printed Name______________________________________________ Signature ______________________________________________ Email _________________________________________________________ Phone_____________________________________________

USE THE ATTACHED MEMBERSHIP FORM TO LIST ALL MEMBERS OF YOUR GROUP


NAMDRC 8618 Westwood Center Drive, Suite 210 Vienna, Virginia 22182-2273

Phone: 703-752-4359 Fax: 703-752-4360 Email: [email protected] Website: www.namdrc.org


NAMDRC INSTITUTIONAL MEMBERSHIP FORM

# NAME ORGANIZATION MAILING ADDRESS EMAIL

1

2

3

4

5

6

7

8

9

10

11

12


NAMDRC 8618 Westwood Center Drive, Suite 210 Vienna, Virginia 22182-2273

Phone: 703-752-4359 Fax: 703-752-4360 Email: [email protected] Website: www.namdrc.org


#

NAME

ORGANIZATION

MAILING ADDRESS

EMAIL

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

# NAME ORGANIZATION MAILING ADDRESS EMAIL 32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

namdrc membership for pulmonary medicine | …comes, such as mortality and complications, patient...

Documents